Table 3 Multivariate analysis showing the impact of the ATG dose as a continuous and a categorical variable (< vs. ≥ 6 mg/kg)

From: Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation

  ATG dose (continuous) ATG dose ≥ 6 mg/kg
  HRa 95 CI p HRa 95 CI p
Acute GVHD 0.98 0.76–1.26 0.856 1.20 0.46–3.09 0.712
Chronic GVHD 0.96 0.63–1.46 0.845 1.01 0.56–1.81 0.980
NRM 1.05 0.80–1.37 0.747 1.49 0.59–3.80 0.399
CIR 1.31 1.12–1.53 0.001 1.85 1.08–3.17 0.024
PFS 1.23 1.08–1.41 0.002 1.74 1.10–2.77 0.019
OS 1.17 1.02–1.35 0.029 1.62 0.98–2.67 0.062
GRFS 1.20 1.01–1.36 0.005 1.64 1.05–2.56 0.028
  1. CIR cumulative incidence of relapse, GVHD graft-vs.-host disease, GRFS GVHD and relapse-free survival, HR hazard ratio, OS overall survival, PFS progression-free survival, 95 CI 95% confidence interval
  2. aHR ratio was adjusted by transplantation period, conditioning regimen, age, cytogenetics, and time from diagnosis to Allo-HSCT